Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Stock Transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reported the conversion and sale of Class A Common Stock on March 5th and 6th, 2025, according to a Form 4 filing.

Summary

• Christopher Gibson, the CEO of Recursion Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 5th and 6th, 2025, Gibson converted Class B Common Stock into Class A Common Stock and subsequently sold 20,000 shares of Class A Common Stock on each day.
• The sales were executed at prices of $6.58 and $6.37 per share, respectively.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 1,256,024 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• He also holds options to purchase a significant number of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock transactions under a pre-existing plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Sales, even under a 10b5-1 plan, can sometimes be interpreted negatively, although pre-planned sales are generally less concerning than discretionary sales.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the biotechnology sector like Recursion Pharmaceuticals, to utilize 10b5-1 trading plans to diversify their holdings and manage personal finances.
• Comparing Gibson's transactions to those of executives at similar-stage biotech companies (e.g., Exscientia, Relay Therapeutics) would require analyzing their Form 4 filings for similar patterns of stock sales and option exercises.
• The size and frequency of these transactions are typical for CEOs of companies of this size.

Stakeholder Impact

• The stock sales could exert downward pressure on the stock price, potentially impacting shareholders.
• The transactions themselves don't directly impact employees, customers, suppliers, or creditors.

Key Dates